These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26588255)

  • 1. Cost-effectiveness analysis of a multivariate index assay compared to modified American College of Obstetricians and Gynecologists criteria and CA-125 in the triage of women with adnexal masses.
    Forde GK; Hornberger J; Michalopoulos S; Bristow RE
    Curr Med Res Opin; 2016; 32(2):321-9. PubMed ID: 26588255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass.
    Havrilesky LJ; Dinan M; Sfakianos GP; Curtis LH; Barnett JC; Van Gorp T; Myers ER
    J Natl Cancer Inst; 2015 Jan; 107(1):322. PubMed ID: 25515232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.
    Coleman RL; Herzog TJ; Chan DW; Munroe DG; Pappas TC; Smith A; Zhang Z; Wolf J
    Am J Obstet Gynecol; 2016 Jul; 215(1):82.e1-82.e11. PubMed ID: 26970494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
    JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
    Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass.
    Bristow RE; Hodeib M; Smith A; Chan DW; Zhang Z; Fung ET; Tewari KS; Munroe DG; Ueland FR
    Am J Obstet Gynecol; 2013 Dec; 209(6):581.e1-8. PubMed ID: 23942039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
    Fust K; Li X; Maschio M; Barron R; Weinstein MC; Parthan A; Walli-Attaei M; Chandler DB; Lyman GH
    Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
    Mehta DA; Hay JW
    Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
    JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
    Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
    J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guideline No. 403: Initial Investigation and Management of Adnexal Masses.
    Salvador S; Scott S; Glanc P; Eiriksson L; Jang JH; Sebastianelli A; Dean E
    J Obstet Gynaecol Can; 2020 Aug; 42(8):1021-1029.e3. PubMed ID: 32736853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.
    Cole AL; Barber EL; Gogate A; Tran AQ; Wheeler SB
    Int J Gynecol Cancer; 2018 Jul; 28(6):1077-1084. PubMed ID: 29683880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
    Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
    Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas.
    Rutstein SE; Siedhoff MT; Geller EJ; Doll KM; Wu JM; Clarke-Pearson DL; Wheeler SB
    J Minim Invasive Gynecol; 2016 Feb; 23(2):223-33. PubMed ID: 26475764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer.
    Longoria TC; Ueland FR; Zhang Z; Chan DW; Smith A; Fung ET; Munroe DG; Bristow RE
    Am J Obstet Gynecol; 2014 Jan; 210(1):78.e1-9. PubMed ID: 24055582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients.
    Eskander RN; Carpenter BA; Wu HG; Wolf JK
    Curr Med Res Opin; 2016 Jun; 32(6):1161-5. PubMed ID: 27052730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of alternative treatments for depression in low-income women.
    Beil H; Beeber LS; Schwartz TA; Lewis G
    J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.